CryoPort opened lower at $20.30, compared with its previous close of $20.56. In the last trading session, the stock traded between $19.49 and $20.37. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in CryoPort is now worth
$ 26.70
Resulting in a loss of
$ 73.30 (73.30%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.45 (-2.21%)
Day High
$20.37
Day Low
$19.49
Day Open
$20.30
Prev Close
$20.56
Volume
4,92,129
1W Return
20.45%
1M Return
19.32%
3M Return
34.58%
6M Return
52.67%
1Y Return
127.19%
Fundamentals
Market Cap ($ Mn)
1,019
PE Ratio
-
PB Ratio
1.83
PEG Ratio
-
ROE
-7.93%
ROCE
-4.52%
EPS (TTM)
$-0.25
Investment Returns
1 Week
20.45%
1 Month
19.32%
3 Months
34.58%
6 Months
52.67%
9 Months
136.54%
Financials
Quarterly
All values in $ Mn
45.5
Jun 25
44.2
Sep 25
45.5
Dec 25
47.8
Mar 26
49.0
Jun 26
50.2
Sep 26
Updates
6Nov
KeyBanc maintains Overweight on CryoPort, raises price target to $20
KeyBanc analyst Paul Knight maintains Overweight rating on CryoPort. Price target raised from $17 to $20. No change in the overall investment recommendation.
6 days ago
6Nov
Needham raises CryoPort price target to $28, maintains Buy rating
Needham raises CryoPort price target from $19 to $28. Analyst David Saxon maintains Buy rating on the stock. Price target increase signals improved valuation outlook.
6 days ago
6Nov
CryoPort Q3FY26 Results: Revenue up 14% to $50.2M, EBITDA positive
Revenue rose 14% YoY to $50.2 million, led by an 18% increase in Life Sciences Services. Adjusted EBITDA turned positive at $1.1 million, a $1.8 million YoY improvement. Full-year FY26 revenue guidance raised to $197 million to $199 million. Clinical trial pipeline hit a record 788 trials, with 99 in Phase 3. Commercial cell and gene therapy revenue grew 20%, supporting 23 active therapies.
7 days ago
18Sep
BTIG Reiterates Buy on CryoPort, Maintains $25 Price Target
BTIG analyst David Larsen reiterates Buy rating on CryoPort. Price target maintained at $25 per share. Stock trades on NASDAQ under ticker CYRX.
1mo ago
7Aug
Needham raises CryoPort price target to $19 on Buy rating
Needham analyst David Saxon maintains a Buy rating on CryoPort Inc. (NASDAQ: CYRX). The firm raised its price target from $15 to $19, reflecting a more optimistic view on the company's prospects.
3mo ago
7Aug
CryoPort Latest Results: Sales guidance affirmed at $192M-$196M
CryoPort confirms its FY26 sales guidance of $192.000M-$196.000M, matching the $194.390M estimate. The reaffirmation indicates stable operational expectations and aligns with market consensus, providing clarity for investors tracking the company's revenue trajectory.
